Schizophrenia ExacerbationMANAGEMENT

PSYCHIATRIC PRESENTATIONS · 12 SECTIONS

⚲

610 items

☷ Legend

⚲

Cardiovascular Presentations71▾

Respiratory Presentations52▾

Neurological Presentations83▾

Gastrointestinal Presentations74▾

Genitourinary and Reproductive Presentations48▾

Infectious Disease Presentations148▾

Trauma Presentations89▾

Toxicologic Presentations80▾

Psychiatric Presentations26▾

Acute anxiety Acute psychosis Agitation-behavioral emergency Anorexia Nervosa (Medical Complications)Bipolar disorder Bipolar Disorder (Depressive Episode)Bipolar Disorder (Manic Episode)Bulimia Nervosa (Medical Complications)Catatonia Conversion disorder Dementia and behavioral crisis Factitious Disorder Failure to Cope (Social)Failure to Thrive Generalized Anxiety Disorder Homicidal Ideation Major Depressive Disorder Major depressive episode Malingering Neuroleptic malignant syndrome Panic Attack Post-Traumatic Stress Disorder (Acute)Schizophrenia Exacerbation Suicidal Ideation Suicidal ideation and attempt Suicide Attempt

Musculoskeletal and Rheumatologic Presentations96▾

Dermatology Presentations23▾

Environmental and Exposure Presentations27▾

Hematologic and Oncologic Presentations36▾

Pediatric-Specific Presentations19▾

Endocrine and Metabolic Presentations45▾

ENT and Maxillofacial Presentations27▾

Ophthalmologic Presentations19▾

Obstetric Presentations23▾

Systemic and Miscellaneous Presentations17▾

01Approach to the Critical Patient/attcp40

Immediate safety priorities

›Exclusion of organic and life-threatening cause

›Delirium must be ruled out before psychiatric disposition

›Fluctuating consciousness, visual hallucinations, abnormal vitals all favor organic cause

›Altered level of consciousness requires full medical workup before behavioral health referral

›Neuroleptic malignant syndrome

›Fever, muscle rigidity, autonomic instability, elevated CK

›Especially if antipsychotic recently started or dose changed

›Substance intoxication or withdrawal

›Methamphetamine, cocaine, PCP, alcohol withdrawal can mimic or worsen psychosis

›CNS infection or encephalitis

›Anti-NMDA receptor encephalitis: young women, seizures, psychiatric symptoms

›Hypoglycemia, hyponatremia, hepatic or uremic encephalopathy

Safety and de-escalation

›Immediate safety measures

›De-escalation techniques as first-line intervention

›Quiet environment, low stimulation, non-threatening posture

›1:1 observation for patients with safety concerns

›Physical restraints only as last resort

›Use trained team only with continuous monitoring

›Document clinical justification

›Psychiatric emergency criteria

›Suicidal ideation with plan or intent

›Homicidal ideation or imminent aggression

›Command hallucinations directing harm to self or others

›Catatonia or grossly disorganized behavior

Monitoring and escalation triggers

›Vital sign targets and monitoring

02History/hx52

Presenting symptoms

›Acute psychotic symptom characterization

›Hallucinations

›Auditory hallucinations: most common in schizophrenia

›Visual hallucinations: raise suspicion for organic etiology

›Command hallucinations directing self-harm or violence

›Delusions

›Persecutory, referential, grandiose, or somatic

›Degree of systematization and conviction

›Disorganized thinking and behavior

›Disorganized speech, loose associations, thought blocking

›Grossly disorganized or catatonic behavior

›Negative symptoms

›Social withdrawal, flat affect, avolition, alogia

Onset and precipitants

›Timeline and triggers

›Onset: acute (hours to days) versus subacute (weeks)

›Identifiable precipitant

›Medication nonadherence: strongest modifiable predictor of relapse, 4-fold increased risk

›Substance use: cannabis and stimulants increase relapse risk 3-fold

›Psychosocial stressors: housing instability, loss of support, recent incarceration

›New medication exposure: steroids, anticholinergics, dopamine agonists, fluoroquinolones

Medication history

›Current and recent antipsychotic use

›Last dose taken and route

›Recent changes, dose reductions, or missed refills

›Prior effective antipsychotics and response profile

›History of NMS, tardive dyskinesia, or acute dystonia

03Physical Exam/exam46

Vital signs

›Vital sign interpretation

›Fever

›Infection, NMS, serotonin syndrome

›Tachycardia

›Stimulant intoxication, NMS, thyrotoxicosis, dehydration

›Hypertension

›Stimulant intoxication, autonomic instability in NMS

›Hypotension

›Dehydration, medication effect, autonomic instability

Mental status examination

›Structured mental status assessment

›Level of consciousness

›Key discriminator between psychosis and delirium

›Fluctuating consciousness favors delirium

›Orientation and memory

›Thought process: linear versus disorganized, tangential, circumstantial

›Thought content: delusions, paranoia, ideas of reference

›Perceptual disturbances: hallucinations type and content

›Affect: blunted, flat, incongruent, labile

›Insight and judgment

›Suicidal and homicidal ideation

Neurologic examination

›Neurologic findings

›Focal motor or sensory deficits

›Suggest intracranial pathology

›Pupil size and reactivity

›Mydriasis: stimulant intoxication

04Differential Diagnosis/ddx48

Cannot-miss organic causes

›Life-threatening diagnoses to exclude first

›Delirium

›ICD-10: F05

›Fluctuating course, visual hallucinations, altered consciousness distinguish from schizophrenia

›Anti-NMDA receptor encephalitis

›ICD-10: G04.81

›Young women, seizures, movement disorder, prominent psychiatric features

›Anti-NMDA receptor antibodies confirmatory

›CNS infection

›Encephalitis (HSV): ICD-10 B00.4

›Bacterial meningitis: ICD-10 G00

›Neurosyphilis: ICD-10 A52.3

›HIV-related CNS disease

›Neuroleptic malignant syndrome

›ICD-10: G21.0

›Fever, rigidity, autonomic instability, elevated CK

›Substance intoxication or withdrawal

›Methamphetamine: ICD-10 F15.120

›PCP: ICD-10 F16.120

›Cocaine: ICD-10 F14.120

›Alcohol withdrawal: ICD-10 F10.232

Psychiatric differential

›Psychiatric conditions mimicking or overlapping

›Bipolar disorder, manic episode with psychotic features

›ICD-10: F31.2

›Elevated mood, grandiosity, decreased sleep, pressured speech

›Major depressive disorder with psychotic features

05Laboratory Tests/lt50

Medical clearance panel

›Targeted laboratory evaluation

›Blood glucose (point-of-care)

›Immediate exclusion of hypoglycemia in altered mental status

›Hyperglycemia: antipsychotic metabolic effect or new-onset diabetes

›Basic metabolic panel

›Electrolytes, renal function, glucose, calcium

›Hyponatremia from psychogenic polydipsia: serum Na <130 mmol/l

›Hypocalcemia or hypercalcemia contributing to altered behavior

Toxicology

›Substance screening

›Urine drug screen

›Cannabis, amphetamines, cocaine, PCP, opioids, benzodiazepines

›Clinical suspicion guides interpretation; positive result does not exclude schizophrenia

›Blood alcohol concentration

›Quantitative level for medical management

›Serum acetaminophen and salicylate

›Indicated in intentional overdose or self-harm concern

Targeted laboratory testing

›Clinically directed investigations

›Complete blood count

›Leukocytosis: infection or NMS

›ANC required if patient on clozapine (REMS requirement)

›Thyroid function tests

›TSH as initial screen for thyroid-related psychosis

›Liver function tests

›Hepatic encephalopathy exclusion

›Baseline before antipsychotic initiation

06Diagnostic Tests/dt73

Scoring Systems

›Clinical assessment tools

›Columbia Suicide Severity Rating Scale (C-SSRS)

›Standardized structured suicide risk assessment

›ACEP notes no tool can reliably identify patients safe for discharge

›Documents ideation intensity, behavior, and lethality

›Positive and Negative Syndrome Scale (PANSS)

›Primary research tool for psychotic symptom severity

›Increase of 12 or more points corresponds to clinically important deterioration

›Less practical for emergency setting

›Clinical Global Impressions-Severity (CGI-S)

›Quick 7-point severity stratification

›Useful for documenting baseline and change

›Abnormal Involuntary Movement Scale (AIMS)

›Screen for tardive dyskinesia before and during antipsychotic treatment

›Score 0-4 for each of 12 body regions

›Brief Psychiatric Rating Scale (BPRS)

›18-item scale for overall psychopathology severity

›Score change of 20% considered clinically meaningful

MRI

›Brain MRI indications and protocol

›Primary indications

›First-episode psychosis: gold standard structural evaluation

›Atypical features: visual hallucinations, focal deficits, abnormal vitals

›Suspicion for CNS pathology: encephalitis, demyelination, tumor

›Not routinely indicated for known schizophrenia with typical exacerbation

›Protocol recommendations

›MRI brain with and without gadolinium contrast

›FLAIR sequences: white matter lesions, encephalitis

›DWI sequences: acute ischemic stroke

›Key findings

›Structural schizophrenia findings: lateral ventricular enlargement, reduced gray matter

›Anti-NMDA receptor encephalitis: FLAIR hyperintensity in limbic regions (50% normal)

›HSV encephalitis: temporal lobe FLAIR signal

›CT head indications

›Indications for non-contrast CT head

›Focal neurologic deficits on examination

›New-onset psychosis in patient older than 40 years without prior psychiatric history

›History of head trauma or falls

›Signs of elevated intracranial pressure

›First-episode psychosis without MRI availability

›Not indicated

›Known schizophrenia with typical exacerbation and no focal neurologic findings

›Routine CT not recommended for psychiatric clearance alone

›CT findings relevant to differential

›Intracranial hemorrhage: subdural, subarachnoid

›Mass lesion: tumor causing psychosis

›Hydrocephalus

Ultrasound

›Ultrasound role

›Limited direct role in schizophrenia exacerbation

›Point-of-care ultrasound for undifferentiated medical emergency

›Cardiac POCUS if hemodynamic instability

›Thyroid ultrasound if goiter or thyroid mass on exam

›Targeted POCUS applications

›Volume status assessment in dehydrated or agitated patient

›Abdominal POCUS if peritonitis or acute abdomen concern

ECG

›Electrocardiogram indications

›QTc monitoring for antipsychotic safety

›Baseline ECG before initiating or changing QTc-prolonging antipsychotic

›QTc >500 ms: consider medication change; torsades de pointes risk

›Prevalence of QTc prolongation on antipsychotics approximately 4%; higher in females and elderly

›High QTc risk antipsychotics

›Sertindole, ziprasidone, amisulpride, thioridazine, IV haloperidol

›Low QTc risk antipsychotics

›Aripiprazole, lurasidone, brexpiprazole

›QTc risk factors

›Female sex, older age, hypokalemia, hypomagnesemia, cardiovascular disease

›Polypharmacy with other QTc-prolonging drugs

EEG

›Electroencephalogram indications

›Suspected seizure disorder

›Postictal psychosis: psychosis following a witnessed or unwitnessed seizure

›Non-convulsive status epilepticus presenting as behavioral change

›Encephalitis workup

›Temporal slow waves in HSV encephalitis

›Delta brush pattern in anti-NMDA receptor encephalitis

07Disposition/dispo36

Admission indications

›Inpatient psychiatric admission criteria

›Safety-based indications

›Suicidal ideation with plan or intent

›Homicidal ideation or aggressive behavior toward identified person

›Command hallucinations threatening safety with compliance risk

›Clinical-based indications

›Inability to care for self or meet basic needs

›Severe disorganization or catatonia

›First-episode psychosis: often warrants inpatient evaluation

›Failed outpatient management or recurrent nonadherence

›Need for involuntary treatment per jurisdictional criteria

Observation indications

›ED observation criteria

›Agitation requiring pharmacologic intervention pending psychiatric evaluation

›Substance intoxication with psychotic features: observe until sober

›Medical comorbidity requiring monitoring before psychiatric transfer

Discharge criteria

›Safe discharge requirements

›Clinical criteria

›Symptom control achieved (control not full remission is the goal)

›No imminent danger to self or others

›Capacity to engage with discharge plan

›Logistical criteria

›Outpatient psychiatric follow-up arranged within 1 week

›Medication plan in place with demonstrated adherence capacity

›Reliable caregiver or support system available

08Treatment/t89

Acute agitation management

›Non-pharmacologic de-escalation

›Verbal de-escalation first-line

›Calm, non-confrontational communication

›Offer of oral medication before IM route

›Reduction of environmental stimulation

›Offer of food, water, or blanket as rapport-building tools

Oral pharmacotherapy for cooperative patient

›Oral options for cooperative patients (ACEP Level B recommendation)

›Olanzapine oral

›Olanzapine 10 mg orally

›Onset approximately 30 to 60 minutes

›Avoid IM benzodiazepine within 1 hour of oral olanzapine

›Risperidone plus lorazepam

›Risperidone 2 mg orally plus lorazepam 2 mg orally

›Combination preferred for moderate agitation

›Haloperidol oral

›Haloperidol 5 mg orally

›May combine with lorazepam 1 to 2 mg orally

Intramuscular pharmacotherapy for uncooperative patient

›IM agents for uncooperative or severe agitation

›Haloperidol IM plus lorazepam IM

›Haloperidol 5 mg IM plus lorazepam 2 mg IM

›Standard first-line combination

›Monitor for respiratory depression

›Olanzapine IM

›Olanzapine 10 mg IM

›Do NOT combine with IM benzodiazepine: risk of respiratory depression and hypotension

›Class I recommendation against concurrent IM olanzapine and IM benzodiazepine

›Droperidol IM

›Droperidol 5 mg IM

›Faster onset than haloperidol

›ACEP Level B recommendation

›Monitor QTc

›Aripiprazole IM

›Aripiprazole 9.75 mg IM

›Lower sedation than olanzapine or droperidol

›Cochrane review: effective for psychosis-induced agitation

›Ketamine IM for refractory severe agitation

›Ketamine 4 to 5 mg/kg IM

›Reserved for agitation refractory to standard agents

›Risk of emergence phenomena

Antipsychotic restart and optimization

›Maintenance antipsychotic management

›Resume prior effective antipsychotic at therapeutic dose

›Most antipsychotics have similar efficacy except clozapine

›If antipsychotic unknown: start second-generation antipsychotic

›Second-generation antipsychotic options

›Risperidone 2 to 6 mg daily

›Olanzapine 10 to 20 mg daily

›Aripiprazole 10 to 30 mg daily

›Quetiapine 400 to 800 mg daily

›Dosing principles

›Target approximately 70% D2 receptor occupancy

›Dose escalation beyond mid-range increases side effects without improving efficacy

›First-episode patients respond to lower doses than multi-episode patients

Long-acting injectable antipsychotics

›LAI antipsychotics for nonadherence

›Indication: recurrent relapse due to medication nonadherence

›LAIs reduce relapse risk: hazard ratio 0.53 versus oral antipsychotics

›Available LAI formulations

›Paliperidone palmitate: monthly or 3-monthly injection

›Aripiprazole lauroxil: monthly or 6-weekly injection

›Risperidone microspheres: biweekly injection

›Haloperidol decanoate: monthly injection

›Initiation in emergency setting

›First-generation LAIs can be initiated in ED after acute stabilization

›Second-generation LAIs require oral overlap period

Treatment-resistant schizophrenia

›Clozapine for treatment-resistant disease

›Indication: failure of 2 or more adequate antipsychotic trials

›Superior efficacy: 30% response rate where others fail

›Clozapine initiation requirements

›REMS enrollment mandatory before prescribing

›Baseline ANC required: ANC >=1.5 x 10^9/L required to initiate

›Weekly ANC monitoring for first 6 months

›Agranulocytosis risk: 1 to 2% incidence

›Starting dose

›Clozapine 12.5 to 25 mg daily with slow uptitration

›Target 300 to 450 mg daily in divided doses

Adjunctive treatments

›Supporting measures

›Electrolyte correction

›Correct hypokalemia and hypomagnesemia before QTc-prolonging agents

›Rehydration for self-neglecting patients

›Benzodiazepines as adjunct for catatonia

›Lorazepam 1 to 2 mg IV test dose for catatonia

NMS management

›Neuroleptic malignant syndrome treatment

›Immediate antipsychotic discontinuation

›Stop all antipsychotic agents immediately

›Supportive care

›Aggressive IV hydration and cooling

›ICU-level monitoring

›Pharmacologic options

›Dantrolene 1 to 2.5 mg/kg IV for severe cases

›Bromocriptine 2.5 mg orally 3 times daily

09Special Populations/sp50

Pregnancy

›Schizophrenia management in pregnancy

›Antipsychotic safety in pregnancy

›Untreated psychosis in pregnancy carries higher risk than antipsychotic exposure

›Most antipsychotics cross placenta (FDA Category C)

›Haloperidol: most data available in pregnancy, generally considered safer option

›Olanzapine and quetiapine: associated with neonatal metabolic effects

›Avoid clozapine in pregnancy when possible: neonatal seizures and myocarditis risk

›Neonatal considerations

›Neonatal extrapyramidal symptoms and withdrawal syndrome with third-trimester exposure

›Monitor neonate for respiratory distress and EPS

›Acute agitation in pregnancy

›Haloperidol IM preferred over benzodiazepines (risk of neonatal respiratory depression)

›Physical restraint in supine position contraindicated after 20 weeks: lateral decubitus position

›Monitoring

›Obstetric consultation for all acutely psychotic pregnant patients

›Fetal monitoring if agitation required pharmacologic intervention

Geriatric

›Schizophrenia exacerbation in older adults

›Late-onset psychosis considerations

›New psychosis after age 60 has higher probability of organic cause

›Lewy body dementia: psychosis with fluctuating cognition, parkinsonism, visual hallucinations

›Avoid antipsychotics in Lewy body dementia: neuroleptic sensitivity, NMS risk

›Pharmacokinetic changes

›Reduced renal and hepatic clearance: use lower doses

›Increased volume of distribution for lipophilic agents

›Higher sensitivity to anticholinergic and sedating effects

›Dose adjustments

10Background/b60

Epidemiology

›Prevalence and incidence

›Global prevalence approximately 0.3 to 0.7% of the population

›Affects approximately 24 million people worldwide

›Annual incidence approximately 15 per 100,000 persons

›Lifetime morbidity and mortality

›Lifetime suicide risk approximately 5%; ideation lifetime prevalence up to 40%

›Life expectancy reduced by 15 to 20 years compared to general population

›Primary causes of death: cardiovascular disease, suicide, respiratory disease

›Relapse epidemiology

›80% of patients experience relapse within 5 years without maintenance treatment

›Relapse rate on antipsychotics: approximately 30% at 1 year

›Prior hospitalization in past year: 3-fold increased relapse risk

›Genetics

›Heritability approximately 80%

›First-degree relatives: approximately 10-fold increased risk

›Sex and age

›Males: typical onset late teens to mid-20s

›Females: typical onset mid-20s to early 30s; second peak after age 40

Pathophysiology

›Neurobiological mechanisms

›Dopamine hypothesis

›Mesolimbic dopamine excess: positive symptoms (hallucinations, delusions)

›Mesocortical dopamine deficiency: negative symptoms and cognitive impairment

›All effective antipsychotics block D2 receptors

›Target D2 occupancy approximately 65 to 80% for efficacy

›Glutamate hypothesis

›NMDA receptor hypofunction contributes to cognitive and negative symptoms

›Mechanism underlying anti-NMDA receptor encephalitis psychosis

›Structural brain changes

›Progressive gray matter reduction with repeated episodes

›Lateral ventricular enlargement present in first episode

›Hippocampal and prefrontal cortex volume reduction

›Neuroinflammatory contributions

›Elevated inflammatory markers during acute episodes

›Microglial activation in cortical regions

›Genetic and environmental interactions

›Polygenic risk score: over 100 genetic loci identified

›Cannabis exposure: dose-dependent increase in psychosis risk

›Obstetric complications, urban upbringing, migration stress as environmental risks

Therapeutic Considerations

›Evidence base and treatment principles

›Antipsychotic efficacy

›All first-line antipsychotics have comparable efficacy except clozapine

›Clozapine superior for treatment-resistant schizophrenia (Class I recommendation)

›Network meta-analysis (Lancet 2026): antidopaminergic and muscarinic agents comparable

›Adherence and relapse prevention

›Medication nonadherence: 4-fold increase in relapse risk

›LAIs reduce relapse hazard ratio to 0.53 versus oral antipsychotics

›Psychoeducation and family involvement reduce relapse risk

›Family expressed emotion (critical comments): 2.3-fold increase in relapse risk

›Metabolic monitoring requirements

›Baseline and annual weight, glucose, lipids for all patients on antipsychotics

›Highest metabolic risk: clozapine and olanzapine

›Lowest metabolic risk: aripiprazole, lurasidone, ziprasidone

›Psychosocial interventions

›Cognitive behavioral therapy for psychosis (CBTp): NICE-recommended adjunct

›Assertive Community Treatment: reduces hospitalizations in high-risk patients

›Coordinated specialty care for first-episode psychosis: improves functional outcomes

›Substance use comorbidity

›Comorbid substance use disorders in approximately 50% of patients

›Cannabis and stimulant use: 3-fold increased relapse risk

›Integrated dual-diagnosis treatment superior to sequential treatment

11Patient Discharge Instructions/pdi33

copy discharge instructions

›Discharge instructions for schizophrenia exacerbation

›Your diagnosis

›You were evaluated for a worsening of your schizophrenia symptoms

›Tests were done to make sure there was no other medical cause for your symptoms

›Your medications

›Take all medications exactly as prescribed

›Do not stop or change your antipsychotic medication without talking to your doctor

›Missing even a few doses greatly increases your risk of symptom return

›If you are having side effects, call your doctor before stopping the medication

›Follow-up appointments

›See your psychiatrist or mental health provider within 1 week

›See your family doctor within 2 to 4 weeks for blood tests and weight check

›Keep all scheduled appointments

›Things to avoid

›Do not use cannabis, cocaine, methamphetamine, or other street drugs

›These substances can cause your symptoms to return quickly

›Avoid alcohol

›Warning signs to watch for

›Return to the emergency department immediately if you develop

›Thoughts of harming yourself or others

›Voices or beliefs that are getting worse or feeling unsafe

›Unable to eat, drink, or take care of yourself

›Fever with muscle stiffness or confusion: this may be a serious medication side effect

›Uncontrolled shaking, muscle spasms, or inability to sit still

›Severe restlessness or pacing that you cannot control

›Recovery expectations

›Agitation and severe distress can improve within hours of treatment

12References/r33

Guidelines and key sources

›Clinical guidelines and policy statements

›ACEP Clinical Policy: Diagnosis and Management of the Adult Psychiatric Patient in the ED

›Nazarian DJ et al. Annals of Emergency Medicine. 2017

›Level B recommendation: IM haloperidol plus lorazepam or IM olanzapine for acute agitation

›Level B recommendation: droperidol effective for acute agitation

›VA/DoD Clinical Practice Guideline for Management of First-Episode Psychosis and Schizophrenia (2023)

›Arias-Reynoso et al. Department of Veterans Affairs 2023

›Comprehensive guidance on relapse prevention, LAIs, metabolic monitoring, psychosocial care

›DSM-5-TR Schizophrenia Criteria

›American Psychiatric Association 2022

Landmark studies and reviews

›Key evidence sources

›Marco CA, Vaughan J. Emergency Management of Agitation in Schizophrenia

›American Journal of Emergency Medicine 2005

›Foundational ED agitation management protocols

›Marder SR, Cannon TD. Schizophrenia. NEJM 2019

›Comprehensive pathophysiology and treatment review

›McCutcheon RA, Reis Marques T, Howes OD. Schizophrenia: An Overview. JAMA Psychiatry 2020

›Epidemiology, biomarkers, and treatment evidence synthesis

›Alvarez-Jimenez M et al. Risk Factors for Relapse Following First Episode Psychosis

›Schizophrenia Research 2012

›Meta-analysis identifying nonadherence and substance use as top relapse predictors

›Brandt L et al. Predicting Psychotic Relapse. Lancet Psychiatry 2023

›LAI antipsychotics reduce relapse HR 0.53 versus oral antipsychotics

›Schneider-Thoma J et al. Comparative Efficacy of Antidopaminergic and Muscarinic Antipsychotics

›Lancet 2026: network meta-analysis of randomised controlled trials

›Siafis S et al. Relapse in Clinically Stable Adults With Schizophrenia. Lancet Psychiatry 2024

Learn More: Schizophrenia Exacerbation→

Comprehensive Clinical Review

Structured, evidence-informed, long-form analysis for deeper understanding.

Evidence & Review

Reviewed by SymptomDx Medical Team · Last reviewed August 18, 2026

SymptomDx is an educational tool for medical professionals. It does not replace clinical judgment. Verify all clinical data and drug dosages with authoritative sources.